White Paper Shows Role of Ongoing Patient Engagement to Improve Rare Disease Clinical Trials, Costs, and Success Rates | PR Newswire [Video]

, /PRNewswire/ — The Global Genes Corporate Alliance, an initiative that brings together biopharmaceutical companies and academic institutions working to improve access and treatments for people with rare diseases, today released a white paper that shows the critical role ongoing patient community engagement through the discovery and drug development process plays in improving the cost, time, and success rates of clinical trials for rare disease therapies. 

The white paper, Early and Often: Reimagining Patient Community Engagement to Improve Clinical Trials Feasibility, argues that by adopting a patient-centric approach, biopharmaceutical companies can enhance protocol designs, improve recruitment and retention, and increase the likelihood of rare disease clinical trials succeeding. The white paper is available to download for free at globalgenes.org. It represents more than a year-long effort of the Global Genes Corporate Alliance and included the participation of members of Global Genes’ Global Advocacy Alliance.

Drug developers often face clinical trial problems because of difficulty recruiting and retaining study …